WarrenAI's 2026 healthcare stock forecast highlights Cigna Corp, Regeneron Pharmaceuticals, Cencora Inc, and Merck & Company as top blue-chip buys. The AI-driven analysis projects significant upside for these companies, citing strong fundamentals and growth potential in a resilient sector. The list emphasizes non-tech equities with robust cash flows and favorable valuations.

Cigna leads with a 51% analyst upside and 145.5% EPS growth forecast, described as a cash-flow machine. Regeneron, a high-margin innovator, follows with 26% upside. Cencora, a pharmaceutical distribution leader, projects 123% EPS growth. Merck rounds out the list as a defensive pharma stock with 21% upside, offering stability through its diverse oncology portfolio.

This forecast arrives as markets reward non-tech blue chips with strong forward prospects. Investors may see these healthcare leaders as hedges against tech volatility, given their solid balance sheets and growth-to-value metrics. The analysis suggests a shift in investor focus toward established companies with predictable earnings and defensive qualities.